Antibody Discovery Market: Rise of Platform Providers

Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody (Ab) discovery based pharmacological interventions, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages, presently represent the largest class of biologics. The antibody discovery market involves a long, arduous and cost intensive process. As a result, many biologics contract manufacturing organizations are opting to outsource such operations. Modern contract research organizations (CROs), offering antibody discovery platform and services, claim to have innovative and advanced technologies to support players developing novel antibody therapy products in their early stage research requirements.


Opinions expressed by eminent industry stakeholders acknowledge the increasing trend of outsourcing and licensing activity within the antibody discovery market.


70+ companies are actively providing services for antibody (Ab) discovery market; of these,11 players claim to have the capabilities to offer services across all discovery stages

Around 60% of the antibody discovery services are focused on lead characterization followed by 25% for lead selection and hit generation.

Presently, a myriad of antibody generation methods are being employed for the discovery of a wide range of monoclonal antibodies and other advanced antibody variants

Over 54% of antibody discovery service providers are focused on non-monoclonal antibodies followed by 32% on monoclonal antibodies.

In fact, players have built sizeable portfolios to offer a wide range of services across various stages of the antibody discovery process.


Over time, several platform providers have also emerged with innovative technologies, designed to augment discovery stage operations in this domain.


These platforms vary considerably in terms of their features as demonstrated by our proprietary product competitiveness analysis.


Growth in number of partnerships reflects the rising interest of stakeholders in this domain; in fact, companies have raised over USD 2.6 billion in financing over the last few years

Various industry and non-industry players have inked deal focusing on antibody discovery. Majority of the deals were licensing agreement.

Driven by the growing demand for therapeutic antibodies, in various novel formats, the market is anticipated to witness steady growth during the coming decade.


Primarily centered in the developed regions, the long term opportunity is likely to be distributed across different types of services related to various stages of the antibody discovery process

The market for antibody discovery services market is fragmented across various segments. North America being the largest share holder.

The sustained growth within the antibody discovery market is expected to result in lucrative monetizing opportunities for platform providers as they compete for a share within the USD 3 billion licensing revenues over the coming decade.


You can also download the SAMPLE REPORT on antibody discovery market by Roots Analysis. 

Our Social Media Platform